EMEA-003245-PIP01-22 - paediatric investigation plan

Lutetium (177Lu) edotreotide

Key facts

• Active Substance:
  Lutetium (177Lu) edotreotide
• Therapeutic area:
  Oncology
• Decision number:
  P/0084/2023
• PIP number:
  EMEA-003245-PIP01-22
• Pharmaceutical form(s):
  Solution for infusion
• Condition(s) / indication(s):
  Treatment of gastro-entero-pancreatic neuroendocrine tumours
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  email: [e-mail] ; tel: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  10/03/2023

Decision

P/0084/2023 : EMA decision of 10 March 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lutetium (177Lu) edotreotide (EMEA-003245-PIP01-22)